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background:  Target specific oral anticoagulants (TSOACs) offer a fixed-dose alternative to warfarin for stroke prevention in patients with 
atrial fibrillation (AF). However, there is minimal evidence to guide the management of bleeding in patients taking a TSOAC. We aimed to 
evaluate the management of bleeding in this patient population at our institution. 
Methods:  We conducted a retrospective cohort analysis of patients with AF who were taking a TSOAC and had a diagnosis of major 
bleeding using the International Society of Thrombosis and Haemostasis criteria. Patients were identified using an electronic health record 
from October 2011 to March 2013. We evaluated management strategies including dialysis, transfusions, pharmacologic agents, and 
reinitiation of anticoagulation. We also assessed laboratory markers for coagulation and mortality. 
results:  We evaluated 578 patients diagnosed with AF who experienced a major bleeding event and had a TSOAC on their current or 
prior medication profile. Of these, 565 were excluded because they were not taking a TSOAC at the time of the bleed. Of the remaining 
thirteen patients, ten were on dabigatran and three were on rivaroxaban. Eight patients were treated for gastrointestinal bleeding; four 
for subarachnoid hemorrhage; and one for a retroperitoneal bleed. No patients received concentrated coagulation factors; five received 
packed red blood cells; two received packed red blood cells and platelets; one received fresh frozen plasma; and one received fresh frozen 
plasma and packed red blood cells. No patients required dialysis and two patients needed surgical interventions. The average hematocrit 
on presentation was 29.1 ± 6.8% and was 33.7 ± 3.7% three days after presentation. Therapeutic anticoagulation was restarted during 
admission on six patients; two were restarted on their anticoagulant, while four received an alternative agent. One patient died during 
hospitalization due to respiratory failure unrelated to the bleeding event. 
Conclusion:  Patients treated for a major bleed while taking a TSOAC at our institution have been managed effectively with supportive 
care without the use of concentrated coagulation factors.
